Oral Atopic Dermatitis Market Crowded, But Arena Sees Room
The company showed improvement on an endpoint used in several Phase III studies of JAK inhibitors, but with a potentially better safety profile.
You may also be interested in...
Amgen said Phase II data are planned for the EADV 2021 meeting, but KHK4083 will need a strong showing.
Arena said its S1P receptor modulator missed the primary endpoint in a Phase IIb trial but data from patients with uninterrupted treatment justify moving etrasimod into a pivotal program.
It has gone under the radar that Eli Lilly and Incyte's Olumiant has recently become the first JAK inhibitor to be approved anywhere for atopic dermatitis and the companies have been touting promising long-term data on the therapy as it expands beyond rheumatoid arthritis.